Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis

Journal of Rheumatology

Volumn 34, Issue 5, 2007, Pages 997-1004

  Mattuzzi, Silvia ^a   Barbi, Stefano ^a   Carletto, Antonio ^a   Ravagnani, Viviana ^a   Moore, Patrick S ^a   Bambara, Lisa Maria ^a   Scarpa, Aldo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Genetic susceptibility; Interleukins; Single nucleotide polymorphism; Systemic sclerosis

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1RN; INTERLEUKIN 2; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLOOD DONOR; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

ADULT; ARTHRALGIA; ARTHRITIS; BIOLOGICAL MARKERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION, PULMONARY; INTERLEUKIN-1BETA; INTERLEUKIN-2; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY FIBROSIS; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED;

EID: 34248677069     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Medsger TA Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000;12:545-8.
2. Klippel JH, Dieppe P. Rheumatology. 2nd ed. London, St. Louis: Mosby; 1998.
3. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
4. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003;49:399-412.
5. Fujii H, Hasegawa M, Takehara K, Mukaida N, Sato S. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 2002;130:548-56.
6. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
7. Alecu M, Geleriu L, Coman G, Galatescu L. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med 1998;36:251-9.
8. Majewski S, Wojas-Pelc A, Malejczyk M, Szymanska E, Jablonska S. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 1999;79:207-10.
9. Widom RL. Regulation of matrix biosynthesis and degradation in systemic sclerosis. Curr Opin Rheumatol 2000;12:534-9.
10. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. Faseb J 2004;18:816-27.
11. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997;24:663-5.
12. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
13. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001;44:1359-62.
14. Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 1996;39:1362-70.
15. Hutyrova B, Lukac J, Bosak V, Buc M, du Bois R, Petrek M. Interleukin lalpha single-nucleotide polymorphism associated with systemic sclerosis. J Rheumatol 2004;31:81-4.
16. Kawaguchi Y, Tochimoto A, Ichikawa N, et al. Association of ILIA gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum 2003;48:186-92.
17. Tsuchiya N, Kuroki K, Fujimoto M, et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004;50:4002-7.
18. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of transforming growth factor beta 1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 2002;61:678-81.
19. Tolusso B, Fabris M, Caporali R, et al. -238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with systemic sclerosis. Immunol Lett 2005;96:103-8.
20. Sato H, Lagan AL, Alexopoulou C, et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 2004;50:558-64.
21. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
22. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
23. Wittke-Thompson JK, Pluzhnikov A, Cox NJ. Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 2005;76:967-86.
24. Cox A, Camp NJ, Nicklin MJ, di Giovine FS, Duff GW. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 1998;62:1180-8.
25. Muraki Y, Tsutsumi A, Takahashi R, et al. Polymorphisms of IL-1 beta gene in Japanese patients with Sjogren's syndrome and systemic lupus erythematosus. J Rheumatol 2004;31:720-5.
26. Genevay S, Di Giovine FS, Perneger TV, et al. Association of interleukin-4 and interleukin-1B gene variants with Larsen score progression in rheumatoid arthritis. Arthritis Rheum 2002;47:303-9.
27. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
28. Hall SK, Perregaux DG, Gabel CA, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum 2004;50:1976-83.
29. Matesanz F, Fedetz M, Leyva L, Delgado C, Fernandez O, Alcina A. Effects of the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic expression. J Neuroimmunol 2004;148:212-7.
30. Hoffmann SC, Stanley EM, Darrin Cox E, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28- stimulated peripheral blood lymphocytes. Transplantation 2001;72:1444-50.
31. Kahaleh MB, LeRoy EC. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 1989;110:446-50.
32. Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL. Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992;65:278-85.
33. Hudson LL, Rocca KM, Kuwana M, Pandey JP. Interleukin-10 genotypes are associated with systemic sclerosis and influence disease-associated autoimmune responses. Genes Immun 2005;6:274-8.
34. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of the 5′ flanking region of the interleukin 10 gene in patients with systemic sclerosis. Rheumatology Oxford 2003;42:1295-8.
35. Carreira PE, Gonzalez-Crespo MR, Ciruelo E, et al. Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population. Arthritis Rheum 2005;52:3015-9.
36. McHugh N, Owen P, Cox B, Dunphy J, Welsh K. MHC Class II, tumour necrosis factor-alpha and lymphotoxin-alpha gene haplotype associations with serological subsets of systemic lupus erythematosus. Ann Rheum Dis 2006;65:488-94. Epub 2005 Aug 17.
37. Pascual M, Nieto A, Mataran L, Balsa A, Pascual-Salcedo D, Martin J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000;1:338-40.
38. Schotte H, Schluter B, Rust S, Assmann G, Domschke W, Gaubitz M. Interleukin-6 promoter polymorphism (-174 G/C) in Caucasian German patients with systemic lupus erythematosus. Rheumatology Oxford 2001;40:393-400.
39. Assassi S, Tan FK. Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays. Curr Opin Rheumatol 2005;17:761-7.
40. Feghali-Bostwick CA. Genetics and proteomics in scleroderma. Curr Rheumatol Rep 2005;7:129-34.